STTK Shattuck Labs7.38+0.31 (+4.4%)
STTK Shattuck Labs6.53+0.24 (+3.8%)
STTK Shattuck Labs6.31+0.30 (+5.0%)
STTK Shattuck Labs4.34+0.07 (+1.6%)
After Hours Gainer
STTK Shattuck Labs4.58-0.22-4.6%
After Hours:5.12+0.54 (+11.8%)
Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8
Globe NewswireFri, 5-Jun 4:05 PM
Premarket Decliner
STTK Shattuck Labs3.49-0.38-9.8%
Premarket:1.43-2.06 (-59.0%)
Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway
Globe NewswireTue, 1-Oct 6:30 AM
